More recently, Nair et al.[25] observed acquired resistance in BRCA wild-type high-grade serous ovarian cancers and attributed resistance to downregulation of CDK1/cyclin B1 prolonging G2 and delaying mitotic catastrophe. This evidence concerns the gene CDK1 and ovarian serous adenocarcinoma.